Doctors decide whether targeted therapy is suitable by combining a confirmed cancer diagnosis with biomarker test results, the cancer’s stage, previous treatments and the patient’s overall health. A mutation or positive test alone does not guarantee that a targeted medicine will help. The most useful question is whether an evidence-based treatment matches your specific tumour and treatment situation.
How Do Doctors Decide if Targeted Therapy Is Right for You?
The decision is more than a single laboratory result. Your oncology team usually reviews five areas: the exact cancer diagnosis, relevant biomarkers, disease stage, past treatments and the likely benefits and risks of an available medicine. A multidisciplinary discussion may be useful in complicated cases. If you are comparing treatment approaches, read our guide to how targeted therapy differs from chemotherapy.
Step 1: Confirm the Cancer Type and Diagnosis
Pathology from a biopsy or surgery helps identify the tumour and its characteristics. A targeted drug used for one cancer type may not be effective or approved for another, even when both show a related molecular alteration. Doctors also review scans, symptoms and other clinical findings to understand the disease.
Step 2: Check Whether the Cancer Has an Actionable Biomarker
What is a cancer biomarker?
A biomarker is a measurable feature, such as a gene alteration or protein expression, that may help inform diagnosis, prognosis or treatment choice. Testing might use tumour tissue or, in some situations, a blood-based circulating tumour DNA test. Results must be interpreted in context.
What does “actionable mutation” mean?
An actionable finding is one that may inform a clinical decision, such as use of a particular drug, further testing or eligibility for a clinical trial. It does not always mean there is an approved treatment suitable for the patient.
Which examples might appear on a cancer report?
| Example marker | Why doctors may check it | Important limitation |
|---|---|---|
| EGFR alteration | Can guide selection of specific medicines in some lung cancers | Not all EGFR variants have the same treatment implications |
| ALK rearrangement | May identify a treatment option in selected lung cancer cases | Must be confirmed with an appropriate test |
| HER2 status | Can guide treatment in selected breast and other cancers | Interpretation depends on cancer type and testing criteria |
| BRAF variant | May inform treatment in selected cancer types | The exact variant and diagnosis matter |
| BRCA-related findings | May help guide some treatment decisions | Inherited and tumour-only findings have different implications |
This table is illustrative, not a recommendation to request every test or start any medicine. A qualified specialist should interpret your individual report.
Step 3: Consider the Cancer Stage and Treatment Goal
A medicine may be supported in metastatic disease but not necessarily in an earlier stage, or vice versa. Doctors consider whether the aim is to lower recurrence risk after other treatment, control disease, relieve symptoms or achieve another clinically appropriate goal. Patients navigating advanced cancer treatment choices or stage 4 cancer options should ask where targeted treatment fits in the complete plan.
Step 4: Review Previous Treatments and Resistance
Prior chemotherapy, immunotherapy, radiation or targeted medicines can affect the next decision. If cancer grows during a targeted treatment, resistance may have developed. Sometimes repeat molecular assessment helps identify a change, but it is not needed or useful in every situation. Review AGH’s guide to what to ask when treatment is not working.
Step 5: Check General Health, Safety and Drug Interactions
Doctors may assess blood counts, liver and kidney function, heart or lung conditions, other medications and the ability to tolerate side effects. Certain targeted therapies can cause significant reactions, and some require monitoring or dose changes. Patients should not start, stop or alter medicines based on an online article.
Does a Positive Biomarker Test Mean You Qualify?
No. A positive result may indicate an option worth discussing, but eligibility also depends on the exact alteration, diagnosis, disease stage, medicine indication, previous treatment and other health considerations. The report may even describe an alteration whose significance is currently uncertain.
What If Your Cancer Has No Targetable Mutation?
That does not mean there are no treatment options. Surgery, radiation, chemotherapy, immunotherapy, hormone therapy and supportive care may still be appropriate depending on the diagnosis. Your doctor can explain whether the original test covered the relevant markers and whether more testing would provide useful information.
Should You Request a Second Opinion on Targeted Therapy?
A second opinion can be helpful when a biomarker report is complicated, different doctors recommend different treatments, the cancer recurs or the next step is unclear. The review should include pathology, test results, scan images and prior treatment records. AGH explains when patients may seek a cancer second opinion, how to prepare for an online cancer second opinion, and how multidisciplinary cancer consultations work.
Seven Questions to Ask Your Oncologist
- Which test result supports the proposed targeted medicine?
- Is the result known to predict response in my specific cancer?
- Is the medicine recommended for my stage and treatment history?
- What benefit is realistic, and what uncertainty remains?
- What common and serious side effects should I watch for?
- How and when will the team check whether it is helping?
- What other standard treatments or trials should we discuss?
How AGH Medical May Support Your Treatment Review
AGH Medical is a patient-support and medical-coordination service, not a hospital. It does not interpret biomarker reports as a treating specialist, prescribe medicines or guarantee eligibility. If you are trying to understand differing recommendations, AGH can help organise documents and coordinate enquiries for a suitable specialist review, including overseas options where appropriate. Speak with the AGH Medical team about reviewing your available reports and possible next steps.
Frequently Asked Questions
Do all cancer patients need biomarker testing?
No. Testing recommendations depend on the type and stage of cancer and the treatments being considered.
Can a blood test replace a tumour biopsy?
Sometimes blood-based molecular testing provides helpful information, but it does not replace tissue diagnosis in all situations. A negative blood result may also require further assessment.
Does a genetic mutation mean targeted therapy will work?
No. The particular variant, tumour type and evidence for a matching medicine all matter.
Is targeted therapy only for stage 4 cancer?
No. Some targeted therapies are used in selected earlier-stage settings as well, depending on the disease and evidence.
Can older adults receive targeted therapy?
Sometimes. Age alone is not the deciding factor; overall health, expected benefit and risks need assessment.
Can targeted therapy be combined with other cancer treatments?
In selected cases, yes. Combining treatments can alter side-effect risks and must be directed by the oncology team.
Who should explain my biomarker report?
Your treating oncologist or another qualified specialist familiar with your diagnosis should explain its clinical significance.
Reliable Medical Sources
- National Cancer Institute: Biomarker Testing for Cancer Treatment
- National Cancer Institute: Targeted Cancer Therapies
Medical disclaimer: This information is educational and does not replace individual medical advice, diagnosis or treatment. Decisions about testing, medicines, risks and timing must be made with a qualified oncology professional.
